The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: Novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation

Blood

Volumn 110, Issue 13, 2007, Pages 4567-4575

  Irei, Toshimitsu ^a   Ohdan, Hideki ^a   Zhou, Wendy ^a   Ishiyama, Kohei ^a   Tanaka, Yuka ^a   Ide, Kentaro ^a   Asahara, Toshimasa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CARBOHYDRATE; CD11B ANTIGEN; CD5 ANTIGEN; CYCLOSPORIN A; FUCOSYLGALACTOSE ALPHA N ACETYLGALACTOSAMINYLTRANSFERASE; IMMUNOGLOBULIN M ANTIBODY; N ACETYLGALACTOSAMINE; ANTIBODY; BLOOD GROUP A TRISACCHARIDE; BOVINE SERUM ALBUMIN; CYCLOSPORIN; OLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP B; BLOOD GROUP O; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHROCYTE; FEMALE; IMMUNIZATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; BLOOD GROUP ABO SYSTEM; CHEMISTRY; DRUG EFFECT; GRAFT REJECTION; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY;

ABO BLOOD-GROUP SYSTEM; ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CYCLOSPORINE; GRAFT REJECTION; HUMANS; LYMPHOCYTE DEPLETION; MICE; OLIGOSACCHARIDES; SERUM ALBUMIN, BOVINE;

EID: 39649122672     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-082719     Document Type: Article

References (46)

1. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med. 2001;11:325-342.
2. Tanaka A, Tanaka K, Kitai T, et al. Living related liver transplantation across ABO blood groups. Transplantation. 1994;58:548-553.
3. Bensinger WI, Baker DA, Buckner CD, Clift RA, Thomas ED. Immunoadsorption for removal of A and B blood-group antibodies. N Engl J Med. 1981;304:160-162.
4. Agishi T, Takahashi K, Yagisawa T, Ota K. Immunoadsorption of anti-A or anti-B antibody for successful kidney transplantation between ABO incompatible pairs and its limitation. Japanese Biosynsorb Research Group. ASAIO Trans. 1991;37:M496-M498.
5. Aikawa A, Ohara T, Hasegawa A, et al. ABO incompatible kidney transplantation on triple therapy compared with quadruple therapy. Transplant Proc. 1998;30:1337-1338.
6. Reding R, Soares M, Baranski A, et al. Preformed antibody and complement rebound after plasma exchange: analysis of immunoglobulin isotypes and effect of splenectomy. Transpl Immunol. 1994;2:231-237.
7. Mor E, Skerrett D, Manzarbeitia C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation. 1995;59:986-990.
8. Hout MS, LeJeune KE, Schaack TM, Bristow DK, Federspiel WJ. Specific removal of anti-A and anti-B antibodies by using modified dialysis filters. Asaio J. 2000;46:702-706.
9. Sanfilippo F. The influence of HLA and ABO antigens on graft rejection and survival. Clin Lab Med. 1991;11:537-550.
10. Toma H, Tanabe K, Tokumoto T. Long-term outcome of ABO-incompatible renal transplantation. Urol Clin North Am. 2001;28:769-780.
11. Hadano T, Ohara T, Aikawa A, Hasegawa A. Significance of antidonor blood type antibody for long-term graft acceptance in ABO-incompatible kidney transplantation. Transplant Proc. 2000;32:1847-1849.
12. Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation. 2000;70:681-685.
13. Zhou W, Ohdan H, Tanaka Y, et al. NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol. 2003;12:9-18.
14. Cong YZ, Rabin E, Wortis HH. Treatment of murine CD5- B cells with anti-Ig, but not LPS, induces surface CD5: two B-cell activation pathways. Int Immunol. 1991;3:467-476.
15. Haughton G, Arnold LW, Whitmore AC, Clarke SH. B-1 cells are made, not born. Immunol Today. 1993;14:84-87.
16. Wortis HH, Teutsch M, Higer M, Zheng J, Parker DC. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci U S A. 1995;92:3348-3352.
17. Hardy RR, Li YS, Allman D, Asano M, Gui M, Hayakawa K. B-cell commitment, development and selection. Immunol Rev. 2000;175:23-32.
18. Arnold LW, McCray SK, Tatu C, Clarke SH. Identification of a precursor to phosphatidyl choline-specific B-1 cells suggesting that B-1 cells differentiate from splenic conventional B cells in vivo: cyclosporin A blocks differentiation to B-1. J Immunol. 2000;164:2924-2930.
19. Ohdan H, Swenson KG, Kruger Gray HS, et al. Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1,3Gal epitopes in alpha 1,3-galactosyltransferase-deficient mice. J Immunol. 2000;165:5518-5529.
20. Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection. J Clin Invest. 1999;104:281-290.
21. Tanaka Y, Ohdan H, Zhou W, et al. Enzymelinked immunospot assay for detecting cells secreting antibodies against human blood group A epitopes. Transplant Proc. 2003;35:555-556.
22. Tanaka Y, Ohdan H, Onoe T, et al. Low incidence of acute rejection after living-donor liver transplantation: immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique. Transplantation. 2005;79:1262-1267.
23. Neron S, Lemieux R. Type 2 T-cell-independent murine immune response to the human ABO blood group antigens. Vox Sang. 1994;67:68-74.
24. Rieben R, Buchs JP, Fluckiger E, Nydegger UE. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories. Transfusion. 1991;31:607-615.
25. Rieben R, Tucci A, Nydegger UE, Zubler RH. Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro. Eur J Immunol. 1992;22:2713-2717.
26. Friedli F, Rieben R, Wegmuller E, Moerenhout M, Nydegger UE. Normal levels of allo- but increased levels of potentially autoreactive antibodies against ABO histo-blood group antigens in AIDS patients. Clin Immunol Immunopathol. 1996;80:96-100.
27. van Rooijen N. Are bacterial endotoxins involved in autoimmunity by CD5+ (Ly-1+) B cells? Immunol Today. 1989;10:334-336.
28. Pillai S. The chosen few? Positive selection and the generation of naive B lymphocytes. Immunity. 1999;10:493-502.
29. Whitmore AC, Haughton G, Arnold LW. Phenotype of B cells responding to the thymus-independent type-2 antigen polyvinyl pyrrolidinone. Int Immunol. 1996;8:533-542.
30. Wuttke NJ, Macardle PJ, Zola H. Blood group antibodies are made by CD5+ and by CD5- B cells. Immunol Cell Biol. 1997;75:478-483.
31. + B cell-dependent regulation of the murine T-cell independent immune response against the human blood group A antigen. Immunol Invest. 1997;26:631-647.
32. McMorrow IM, Comrack CA, Nazarey PP, Sachs DH, DerSimonian H. Relationship between ABO blood group and levels of Gal alpha,3Galactose-reactive human immunoglobulin G. Transplantation. 1997;64:546-549.
33. Kawahara T, Ohdan H, Zhao G, Yang YG, Sykes M. Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J Immunol. 2003;171:5406-5414.
34. Aksentijevich I, Sachs DH, Sykes M. Natural antibodies against bone marrow cells of a concordant xenogeneic species. J Immunol. 1991;147:79-85.
35. Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U. Elimination of anti-Gal B cells by alpha-Gal ricin1. Transplantation. 2002;73:1859-1868.
36. Kunkl A, Klaus GG. Selective effects of cyclosporin A on functional B cell subsets in the mouse. J Immunol. 1980;125:2526-2531.
37. Dobbeling U. The effects of cyclosporin A on V(D)J recombination activity. Scand J Immunol. 1997;45:494-498.
38. Venkataraman L, Francis DA, Wang Z, Liu J, Rothstein TL, Sen R. Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity. 1994;1:189-196.
39. Wu A, Buhler LH, Cooper DK. ABO-incompatible organ and bone marrow transplantation: current status. Transpl Int. 2003;16:291-299.
40. Cacciarelli TV, So SK, Lim J, Concepcion W, Cox K, Esquivel CO. A reassessment of ABO incompatibility in pediatric liver transplantation. Transplantation. 1995;60:757-760.
41. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med. 2001;344:793-800.
42. Gennery AR, Cant AJ, Spickett GP, et al. Effect of immunosuppression after cardiac transplantation in early childhood on antibody response to polysaccharide antigen. Lancet. 1998;351:1778-1781.
43. Springer GF, Horton RE. Blood group isoantibody stimulation in man by feeding blood group-active bacteria. J Clin Invest. 1969;48:1280-1291.
44. Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion. 1974;14:551-559.
45. Fan X, Ang A, Pollock-Barziv SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med. 2004;10:1227-1233.
46. Ohdan H, Zhou W, Tanaka Y, et al. Evidence of immune tolerance to blood group antigens in a case of ABO-incompatible pediatric liver transplantation. Am J Transplant. 2007;7:2190-2194.